Phase I/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30 subjects with AL amyloidosis. Expansion phase to evaluate safety, efficacy and pharmacokinetics of NEOD001 in 25 additional subjects at the maximum tolerated dose.

Principal Investigator

  • Steven Coutre

Stanford Investigator(s)

  • Michaela Liedtke


Primary Contact:
Ying Hao
(650) 723-0646